Neuroendocrine differentiation after neoadjuvant hormonal treatment in prostate cancer

R. Autorino, G. Di Lorenzo, F. P. D'Armiento, C. Mignogna, L. Cindolo, M. De Sio, S. Perdona, E. De Fortuna, L. Salzano, S. De Placido, M. D'Armiento

Research output: Contribution to journalArticle

Abstract

Aim. Neuroendocrine (NE) differentiation occurs in various degree in the majority of prostatic adenocarcinomas and it has been correlated with tumor progression and poor prognosis. There is little knowledge about the impact of NE differentiation on tumor response to neoadjuvant hormonal treatment (NHT). The role of NE differentiation as a marker of recurrence after radical prostatectomy (RP) is also unclear. We evaluated 'whether there is an increase in NE differentiation during the course of NHT and whether the tumor relapse after radical surgery correlates with the extent of NE differentiation. Methods. RP specimens from 44 patients submitted to 3 months of NHT and RP specimens from 40 nonpretreated patients were histologically assessed. Staining for NE differentiated prostate tumor cells was carried out using a specific monoclonal antibody against chromogranin A (CgA). Results. CgA positive cells were found in 4 of 40 patients (10%) in the RP group and in 4 of 44 patients (9%) of the NHT+RP group. At follow-up, we had 21 biochemically relapsed patients. Among them, 6 were CgA positive (75% of 8 patients), whereas is were CgA negative (20% of 76 patients). Conclusion. The NE differentiation doesn't increase after NHT. Although not statistically significant a trend to higher risk of relapse among the chromogranin positive samples was observed. The significance of NE differentiation in the progression of the disease and its relation to other known prognostic factors remains unclear.

Original languageEnglish
Pages (from-to)319-324
Number of pages6
JournalMinerva Urologica e Nefrologica
Volume57
Issue number4
Publication statusPublished - Dec 2005

Fingerprint

Neoadjuvant Therapy
Prostatic Neoplasms
Prostatectomy
Chromogranin A
Recurrence
Neoplasms
Chromogranins
Disease Progression
Prostate
Adenocarcinoma
Monoclonal Antibodies
Staining and Labeling

Keywords

  • Neoadjuvant hormonal therapy
  • Neuroendocrine differentiation
  • Prostatic neoplasms
  • Radical prostatectomy

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Autorino, R., Di Lorenzo, G., D'Armiento, F. P., Mignogna, C., Cindolo, L., De Sio, M., ... D'Armiento, M. (2005). Neuroendocrine differentiation after neoadjuvant hormonal treatment in prostate cancer. Minerva Urologica e Nefrologica, 57(4), 319-324.

Neuroendocrine differentiation after neoadjuvant hormonal treatment in prostate cancer. / Autorino, R.; Di Lorenzo, G.; D'Armiento, F. P.; Mignogna, C.; Cindolo, L.; De Sio, M.; Perdona, S.; De Fortuna, E.; Salzano, L.; De Placido, S.; D'Armiento, M.

In: Minerva Urologica e Nefrologica, Vol. 57, No. 4, 12.2005, p. 319-324.

Research output: Contribution to journalArticle

Autorino, R, Di Lorenzo, G, D'Armiento, FP, Mignogna, C, Cindolo, L, De Sio, M, Perdona, S, De Fortuna, E, Salzano, L, De Placido, S & D'Armiento, M 2005, 'Neuroendocrine differentiation after neoadjuvant hormonal treatment in prostate cancer', Minerva Urologica e Nefrologica, vol. 57, no. 4, pp. 319-324.
Autorino R, Di Lorenzo G, D'Armiento FP, Mignogna C, Cindolo L, De Sio M et al. Neuroendocrine differentiation after neoadjuvant hormonal treatment in prostate cancer. Minerva Urologica e Nefrologica. 2005 Dec;57(4):319-324.
Autorino, R. ; Di Lorenzo, G. ; D'Armiento, F. P. ; Mignogna, C. ; Cindolo, L. ; De Sio, M. ; Perdona, S. ; De Fortuna, E. ; Salzano, L. ; De Placido, S. ; D'Armiento, M. / Neuroendocrine differentiation after neoadjuvant hormonal treatment in prostate cancer. In: Minerva Urologica e Nefrologica. 2005 ; Vol. 57, No. 4. pp. 319-324.
@article{445cc64f082f4e5db29ef7f5ef1e1f6d,
title = "Neuroendocrine differentiation after neoadjuvant hormonal treatment in prostate cancer",
abstract = "Aim. Neuroendocrine (NE) differentiation occurs in various degree in the majority of prostatic adenocarcinomas and it has been correlated with tumor progression and poor prognosis. There is little knowledge about the impact of NE differentiation on tumor response to neoadjuvant hormonal treatment (NHT). The role of NE differentiation as a marker of recurrence after radical prostatectomy (RP) is also unclear. We evaluated 'whether there is an increase in NE differentiation during the course of NHT and whether the tumor relapse after radical surgery correlates with the extent of NE differentiation. Methods. RP specimens from 44 patients submitted to 3 months of NHT and RP specimens from 40 nonpretreated patients were histologically assessed. Staining for NE differentiated prostate tumor cells was carried out using a specific monoclonal antibody against chromogranin A (CgA). Results. CgA positive cells were found in 4 of 40 patients (10{\%}) in the RP group and in 4 of 44 patients (9{\%}) of the NHT+RP group. At follow-up, we had 21 biochemically relapsed patients. Among them, 6 were CgA positive (75{\%} of 8 patients), whereas is were CgA negative (20{\%} of 76 patients). Conclusion. The NE differentiation doesn't increase after NHT. Although not statistically significant a trend to higher risk of relapse among the chromogranin positive samples was observed. The significance of NE differentiation in the progression of the disease and its relation to other known prognostic factors remains unclear.",
keywords = "Neoadjuvant hormonal therapy, Neuroendocrine differentiation, Prostatic neoplasms, Radical prostatectomy",
author = "R. Autorino and {Di Lorenzo}, G. and D'Armiento, {F. P.} and C. Mignogna and L. Cindolo and {De Sio}, M. and S. Perdona and {De Fortuna}, E. and L. Salzano and {De Placido}, S. and M. D'Armiento",
year = "2005",
month = "12",
language = "English",
volume = "57",
pages = "319--324",
journal = "Minerva Urologica e Nefrologica",
issn = "0393-2249",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - Neuroendocrine differentiation after neoadjuvant hormonal treatment in prostate cancer

AU - Autorino, R.

AU - Di Lorenzo, G.

AU - D'Armiento, F. P.

AU - Mignogna, C.

AU - Cindolo, L.

AU - De Sio, M.

AU - Perdona, S.

AU - De Fortuna, E.

AU - Salzano, L.

AU - De Placido, S.

AU - D'Armiento, M.

PY - 2005/12

Y1 - 2005/12

N2 - Aim. Neuroendocrine (NE) differentiation occurs in various degree in the majority of prostatic adenocarcinomas and it has been correlated with tumor progression and poor prognosis. There is little knowledge about the impact of NE differentiation on tumor response to neoadjuvant hormonal treatment (NHT). The role of NE differentiation as a marker of recurrence after radical prostatectomy (RP) is also unclear. We evaluated 'whether there is an increase in NE differentiation during the course of NHT and whether the tumor relapse after radical surgery correlates with the extent of NE differentiation. Methods. RP specimens from 44 patients submitted to 3 months of NHT and RP specimens from 40 nonpretreated patients were histologically assessed. Staining for NE differentiated prostate tumor cells was carried out using a specific monoclonal antibody against chromogranin A (CgA). Results. CgA positive cells were found in 4 of 40 patients (10%) in the RP group and in 4 of 44 patients (9%) of the NHT+RP group. At follow-up, we had 21 biochemically relapsed patients. Among them, 6 were CgA positive (75% of 8 patients), whereas is were CgA negative (20% of 76 patients). Conclusion. The NE differentiation doesn't increase after NHT. Although not statistically significant a trend to higher risk of relapse among the chromogranin positive samples was observed. The significance of NE differentiation in the progression of the disease and its relation to other known prognostic factors remains unclear.

AB - Aim. Neuroendocrine (NE) differentiation occurs in various degree in the majority of prostatic adenocarcinomas and it has been correlated with tumor progression and poor prognosis. There is little knowledge about the impact of NE differentiation on tumor response to neoadjuvant hormonal treatment (NHT). The role of NE differentiation as a marker of recurrence after radical prostatectomy (RP) is also unclear. We evaluated 'whether there is an increase in NE differentiation during the course of NHT and whether the tumor relapse after radical surgery correlates with the extent of NE differentiation. Methods. RP specimens from 44 patients submitted to 3 months of NHT and RP specimens from 40 nonpretreated patients were histologically assessed. Staining for NE differentiated prostate tumor cells was carried out using a specific monoclonal antibody against chromogranin A (CgA). Results. CgA positive cells were found in 4 of 40 patients (10%) in the RP group and in 4 of 44 patients (9%) of the NHT+RP group. At follow-up, we had 21 biochemically relapsed patients. Among them, 6 were CgA positive (75% of 8 patients), whereas is were CgA negative (20% of 76 patients). Conclusion. The NE differentiation doesn't increase after NHT. Although not statistically significant a trend to higher risk of relapse among the chromogranin positive samples was observed. The significance of NE differentiation in the progression of the disease and its relation to other known prognostic factors remains unclear.

KW - Neoadjuvant hormonal therapy

KW - Neuroendocrine differentiation

KW - Prostatic neoplasms

KW - Radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=28544433368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28544433368&partnerID=8YFLogxK

M3 - Article

C2 - 16247353

AN - SCOPUS:28544433368

VL - 57

SP - 319

EP - 324

JO - Minerva Urologica e Nefrologica

JF - Minerva Urologica e Nefrologica

SN - 0393-2249

IS - 4

ER -